Safety Study of Abatacept in Rheumatoid Arthritis Participants
| Status: | Completed |
|---|---|
| Conditions: | Arthritis, Rheumatoid Arthritis |
| Therapuetic Areas: | Rheumatology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 10/6/2018 |
| Start Date: | December 17, 2015 |
| End Date: | June 29, 2018 |
Comparative Safety of Biologic Disease-modifying Treatment Initiation With Abatacept in Rheumatoid Arthritis: A Real-world Population-based Observational Study
A observational study to assess whether biologic disease-modifying (BDM) treatment initiation
with abatacept for rheumatoid arthritis is associated with an increased risk of serious
infection and cancer
with abatacept for rheumatoid arthritis is associated with an increased risk of serious
infection and cancer
Inclusion Criteria:
- Patient initiates BDM treatment with at least one claim for the treatment. Patients
will be presumed to be new users of a treatment if there is no claim for the drug or
any other BDM in the 180 days prior to the cohort entry date
- Patient has at least two diagnoses for RA in the patient's history prior to and
including the entry date or within the 180 days after the entry date
- Patient is aged 18 years or older on the entry date
- Patient was enrolled in the database for at least 180 days before the entry date
Exclusion Criteria:
- Patient is younger than 18 years on the entry date
- Patients who receive abatacept and another biologic simultaneously
- Patients who have an outcome diagnosis in the baseline period will be excluded from
the cohort analyses for that outcome
Other protocol defined inclusion/exclusion criteria could apply
We found this trial at
1
site
Click here to add this to my saved trials
